Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Worel, N; Rosskopf, K; Neumeister, P; Kasparu, H; Nachbaur, D; Russ, G; Namberger, K; Witt, V; Schloegl, E; Zojer, N; Linkesch, W; Kalhs, P; Greinix, HT.
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Transfusion. 2011; 51(5):968-975
Doi: 10.1111/j.1537-2995.2010.02896.x
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Greinix Hildegard
- Linkesch Werner
- Neumeister Peter
- Rosskopf Konrad
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) has been shown to enhance stem cell mobilization in patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease who demonstrated with previous mobilization failure. In this named patient program we report the Austrian experience in insufficiently mobilizing patients. Twenty-seven patients from eight Austrian centers with a median (range) age of 58 (19-70) years (18 female, nine male) were included in the study. Plerixafor was limited to patients with previous stem cell mobilization failure and was given in the evening of Day 4 of G-CSF application. A median increase of circulating CD34+ cells within 10 to 11 hours from administration of plerixafor by a factor of 4.7 over baseline was noted. Overall, 20 (74%) patients reached more than 10 × 10(6) CD34+ cells/L in the peripheral blood, resulting in 17 (63%) patients collecting at least 2 × 10(6) CD34+ cells/kg body weight (b.w.; median, 2.6 × 10(6) CD34+ cells/kg b.w.; range, 0.08 × 10(6) -8.07 × 10(6) ). Adverse events of plerixafor were mild to moderate and consisted of gastrointestinal side effects and local reactions at the injection site. Thirteen (48%) patients underwent autologous transplantation receiving a median of 2.93 × 10(6) CD34+ cells/kg (range, 1.46 × 10(6) -5.6 × 10(6) ) and showed a trilinear engraftment with a median neutrophil recovery on Day 12 and a platelet recovery on Day 14. Our study confirms previous investigations showing that plerixafor in combination with G-CSF is an effective and well-tolerated mobilization regimen with the potential of successful stem cell collection in patients with previous mobilization failure. © 2010 American Association of Blood Banks.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Antigens, CD34 - metabolism
- Antigens, CD34 -
- Combined Modality Therapy -
- Drug Therapy, Combination -
- Female -
- Granulocyte Colony-Stimulating Factor - administration & dosage
- Hematopoietic Stem Cell Mobilization - methods
- Hematopoietic Stem Cell Transplantation - methods
- Hematopoietic Stem Cells - cytology Hematopoietic Stem Cells - metabolism
- Heterocyclic Compounds - administration & dosage
- Humans -
- Immunoglobulin G - therapeutic use
- Leukapheresis -
- Lymphoma - drug therapy
- Male -
- Melphalan - therapeutic use
- Middle Aged -
- Multiple Myeloma - drug therapy
- Receptors, CXCR4 - antagonists & inhibitors
- Transplantation, Autologous -
- Young Adult -